ProKidney Corp.
Jill Kuharsky is a skilled research associate currently working at ProKidney Corp. since August 2022, with prior experience as a manufacturing specialist at Twin City Bio from October 2016 to August 2022, where responsibilities included cell culture, SOP revision, and process improvement within GMP, GLP, and GDP frameworks. Jill began their career in research as an undergraduate research assistant at Guilford College, contributing to studies on bioaccumulation and biomagnification and facilitating collaborations with Wake Forest University. Presenting research at national conferences highlighted Jill's commitment to scientific inquiry. Additionally, Jill has experience as a teacher assistant in the Biology Department and has a strong background in customer service from working at Outback Steakhouse. Jill holds a Bachelor's Degree in Biology from Guilford College, graduated in 2016.
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.